Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 2/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955170 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| Hydrochloric Acid SCHEMBL7124230 | 0.98 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| SCHEMBL10966874 | 0.85 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| SCHEMBL29954598 | 0.85 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| SCHEMBL6650089 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| SCHEMBL9607638 | 0.79 | POLB (0.49) | ALDH1A1TSHRTDP1CYP3A4ACHE | |
| SCHEMBL29957247 | 0.78 | HSD17B10 (0.60) | ALDH1A1TSHRTDP1HSD17B10MAPT | |
| SCHEMBL2627236 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRTDP1CYP3A4HSD17B10 | |
| SCHEMBL13303843 | 0.78 | HSD17B10 (0.60) | ALDH1A1TSHRTDP1HSD17B10MAPT | |
| SCHEMBL13414579 | 0.78 | CYP3A4 (0.55) | ALDH1A1TSHRTDP1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | ALDH1A1 2444/4885TSHR 2827/4885TDP1 1543/4885 |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | ALDH1A1 569/4885TSHR 2698/4885TDP1 1414/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | ALDH1A1 587/4885TSHR 67/4885TDP1 3939/4885 |
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | ALDH1A1 1680/4885TSHR 229/4885TDP1 4245/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | ALDH1A1 2444/4885TSHR 2827/4885TDP1 1543/4885 |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | ALDH1A1 2182/4885TSHR 402/4885TDP1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.